Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 01/11/22
End: 08/31/29
Due: 08/31/30
Phase: N/A
Priority: Normal
Start: 03/18/21
End: 03/31/26
Due: 03/31/27
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | NCT05081609 | Ascendis Pharma Oncology Division A/S | user2@example.com | None | 2022-01-11 | 2029-08-31 | 2030-08-31 | - | - | 2025-07-14 |
| A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors | NCT04799054 | Ascendis Pharma Oncology Division A/S | user2@example.com | None | 2021-03-18 | 2026-03-31 | 2027-03-31 | - | - | 2025-07-14 |